Early prediction of drug-induced toxicity is needed in the pharmaceutical and biotechnology industries to decrease late-stage drug attrition.
Specifically, oncology drugs have become more effective in extending the lives of patients suffering from cancer. This improved prognosis, however, is giving more time for anti-cancer drugs to exert toxic effects such as cardiotoxicity, neuropathy and more.
Novel human cell models, such as human induced pluripotent stem cell (iPSC)-derived cell types, are needed to reliably and cost-effectively predict drug-related toxicities at the preclinical stage. iPSC-derived cells provide a flexible, high value human cellular system that offers a highly translational and typically more predictive cellular environment than immortalized cell lines or even primary rodent models.
This webinar will describe proof-of-concept studies of how induced pluripotent stem cell-derived cells can predict cardiac and neuronal side effects caused by oncology compounds
Register now and discover how human cardiac and neuronal cells, derived from induced pluripotent stem cells (iPSC), are playing a rapidly increasing role in in vitro safety and discovery approaches for oncology compounds.
Whether you are screening for new oncology drug targets, or investigating drug effects on cellular structure or function, this webinar will provide insights for your own research.
Eileen Dolan, PhD
Professor of Medicine, Section of Hematology/Oncology, University of Chicago
Dr. M. Eileen Dolan, Professor of Medicine, is Chair of the Committee on Clinical Pharmacology and Pharmacogenomics that includes a board-certified training program for clinical and post-doctoral fellows at the University of Chicago. Within the University of Chicago Medicine Comprehensive Cancer Center, she serves as the Associate Director for Education and is co-leader of the Clinical and Experimental Therapeutics Program.
She directs a Graduate Training Program in Breast Cancer Disparities including creating a graduate level course in breast cancer disparities. She recently received the University of Chicago BSD Distinguished Faculty Educator/Mentor award. Her research is highly translational.
She has a broad background in pharmacology, and specific expertise in pharmacogenomics of anticancer agent toxicity using both clinical genome wide association studies and preclinical studies to identify and functionally validate genes/genetic variants associated with adverse drug reactions. She has recently developed cell-based methods using induced pluripotent stem cells to study chemotherapy induced peripheral neuropathy. She has over 200 peer-reviewed, original research publications and approximately 60 editorials/book chapters/reviews.
Since 2000, she has been continuously funded in the area of pharmacogenomics and previous to that, held continuous funding for her work in DNA repair.
Ivan Kopljar, PhD
Scientist at Janssen, Pharmaceutical Companies of Johnson & Johnson.
Greg Luerman, PhD
Technical Director, North America, Axiogenesis
- Learn how iPSC-derived cell types are used in oncology-related screening/safety applications, and how they help “humanizing” drug discovery / development
- Gain insight into 'real-world' examples / case studies from experts in the area of cardio- and neuro-oncology
- Understand how Axiogenesis’ products and services support your cardio- and neurotoxicity-related applications
- Preclinical Research
- Drug Discovery
- Cardiovascular Safety
- Safety Pharmacology
- Toxicology
- Neuropharmacology
- Preclinical (Assay) Development
- Target Discovery
- Screening Labs
- Stem Cell Engineering
- Discovery Sciences
- Translational Research
